Active Pharmaceutical Ingredients (APIs) have been an integral part of the pharmaceutical business for ages. However, over the last few years, the weakness of global supply chains has been proven. Pandemic, geopolitical conflicts, surge in logistics expenses, and raw material shortages have been among the many hurdles for API sourcing for pharmaceutical firms.
API Supply Chain will be more diversified, technology based and resilient in the world till 2030.
The days of the simple price purchase have passed. In place of, however, they must think about cost, quality, compliance, and the security of supply.
Being aware of the future direction of the industry can help manufacturers, distributors, exports and procurement professionals to make informed sourcing decisions.
This API market continues to increase as the demand for healthcare is growing, the world's population is aging, and chronic diseases are becoming more common, while also seeing a surge in pharmaceutical production.
Historically, API production has been very concentrated in some geographic areas, particularly China and India. These countries continue to be of significance in global pharmaceutical manufacturing, but the recent turmoil has pointed to the dangers of over-dependency on any one sourcing location.
Pharma companies now give more attention to SC resilience. There are more than price considerations for procurement teams, with supplier diversity, regulatory compliance, manufacturing capabilities, and long-term reliability among some of the new considerations as well.
This change is changing the way organizations identify, score and manage API suppliers.
One of the most significant trends influencing the API market is supplier diversification.
In the past, numerous pharmaceutical firms depended mainly on the drug supplies from one country. Although this was relatively cost efficient, this practice also left businesses at risk from anything that could affect the business, such as trade policies, geopolitical shifts, transportation problems or regulation.
Within the next five years (2025-2030), procurement professionals should begin the process of multi-country contracting. They can help reduce risk and maintain business continuity through their relationship with suppliers across different areas.
The focus will increasingly be on a stable and resilient supplier chain as opposed to the cheapest supplier.
India is one of the leading pharmaceutical manufacturing countries in the world.
The country has several benefits:
Meanwhile, Government programs for the enhancement of domestic API production are also contributing to the industry's expansion.
API suppliers in India are likely to become more important in the global sourcing strategies as global pharmaceutical companies look for alternatives and other sources.
India is emerging as a preferred location for generic as well as specialty APIs for buyers looking to find reliable manufacturing partners.
The principles of transparency are emerging as a key requirement in the acquisition of pharmaceutical products.
Businesses need to understand who they are purchasing from, how they are actually made, their quality assurance process, as well as their regulatory compliance. There is a need for consumer and regulator expectations of increased accountability in the supply chain.
The trend is fueling the demand for:
The more transparent the organization, the more competitive it will be in the world market.
Traditional procurement approaches are frequently based on spreadsheets, emails, phone calls and manual supplier searches.
In a more complex international supply chain, these methods are still not proving to be effective for small-scale operations.
Digital procurement platforms are assisting companies in the following ways:
Digital Sourcing Ecosystems will be the norm in the Pharmaceutical Sector by 2030.
Those businesses that stick to manual procurement methods are likely to face difficulty to adjust their operations with the fluctuations of the market.
In the past, procurement was mostly about the lowest price.
But recent upsets have shown that the cheapest is not necessarily the best.
Going forward, procurement activities will be more focused on:
Firms will start to assess their suppliers on their capacity to deliver consistently with fluctuating market conditions.
Now that technology and sourcing methods have come a long way, the procurement of APIs will still be a challenge.
There are still ongoing changes in pharmaceutical regulations in various markets. Procurement teams need to ensure that suppliers are able to comply with relevant quality and compliance requirements and that they are ready to comply with regulatory changes.
The continuously moving raw material price can make a big difference in API prices. The uncertainty in price may be due to the global economic condition, energy prices or the ratio of supply and demand.
Supply chain performance could be affected by delays in transport, congestion at ports, political events, and increasing costs of transport.
However, in cases where supply chain disruptions happen, the relationship between suppliers can also be adversely affected.
Finding and confirming good suppliers is still a lengthy process.
Before making procurement decisions, procurement teams need to assess manufacturing capabilities, certifications, quality systems, compliance records, production capacity, etc.
It becomes even more complex in a more and more global supply chain.
Proactiveness with the API supply chain will pay off for the organizations that take the initiative in adopting it.
To reduce the risk and resilience of procurement, a combination of suppliers and/or regions can be used.
Assessments of suppliers are conducted regularly to maintain quality, compliance, and reliability of operations.
Savvy pricing, supply-demand and regulatory market trends can help make better procurement decisions.
As a rule, any automation or digital sourcing tools will boost efficiency and decrease manual work.
Good partnerships can offer a more flexible response when markets disrupt and continuity of supply.
The pharmaceutical sector in India has grown into a significant contributor to the world's healthcare manufacturing sector.
It is becoming increasingly relevant for a variety of reasons:
There are also a variety of pharmaceutical manufacturing firms in India with a large manufacturing capacity in all the product categories.
Over the years, the pharmaceutical industry has developed a highly trained staff to comply with international pharmaceutical quality standards.
Many manufacturers in India are subject to a high degree of regulatory obligations and market their products in markets with strict regulations globally.
India still has the edge when it comes to manufacturing quality and technical expertise, as well as the price.
India's contribution to the API supply chain will be much higher in the near future as global pharmaceuticals companies are looking for reliable sourcing partners.
However, for the process of API sourcing to be successful, it requires more than that of looking for suppliers in a constantly evolving environment. Having access to credible data, trustworthy sources of suppliers and effective sourcing solutions is vital for businesses.
ChemDmart is an integrated platform for sourcing within the pharmaceuticals and chemicals industry.
The platform allows companies to:
With one platform, procurement teams can find and-source suppliers more efficiently, versus a bunch of sourcing methods.
Between 2025 and 2030, digital procurement platforms will be instrumental to businesses' ability to deal with risk and supply continuity in a much more complex supply chain.
The worldwide API supply chain is undergoing important change. With pricing one of the most important factor, security, transparency, compliance and resilience are just as important.
In next 5 years, three trends will dominate the markets of pharmaceuticals supply: supplier diversification, digital procurement and improved supplier networks. API suppliers in India are then going to become all the more critical in serving the demand for the pharmaceutical industry in the rest of the world.
What will be key to success will be for procurement teams to employ "smarter" sourcing strategies, gain access to market intelligence, and develop resilient supplier ecosystems capable of withstanding future shocks.
